Renal glucose handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

Diabetes Care

Volumn 36, Issue 5, 2013, Pages 1260-1265

  Ferrannini, Ele ^a   Veltkamp, Stephan A ^b   Smulders, Ronald A ^b   Kadokura, Takeshi ^c  

^a UNIVERSITY OF PISA   (Italy)

^b Astellas Pharma Global Development Europe   (Netherlands)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIURIA; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; POTASSIUM BLOOD LEVEL; QUANTITATIVE ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; URINARY EXCRETION; VERTIGO;

AGED; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE; GLUCOSIDES; GLYCOSURIA; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84876803427     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1503     Document Type: Article

References (24)

1. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342 (Pubitemid 38101606)
2. Chao EC, Henry RR.SGLT2 inhibitionda novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559
3. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397-404
4. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-794
5. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22:104-112
6. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8: 495-502
7. Veltkamp SA, Kadokura T, Krauwinkel WJJ, Smulders RA. Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, stimulates urinary glucose excretion in healthy subjects. Clin Drug Investig 2011;31:839-851
8. Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglyce-mia in healthy Japanese subjects. Diabetol Int 2011;2:172-182
9. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S. ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus. Abstract 75-OR. Presented at the 70th Scientific Sessions of the American Diabetes Association Annual Meeting; 24-28 June 2010; Orlando, Florida.
10. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011;13:1219-1227
11. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacody-namics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357-365
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
13. Matsuo S, Imai E, Horio M, et al.; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992
14. Freijer J, Krauwinkel W, Kadokura T, Zhang W, Smulders R. PK/PD model for ASP1941, a novel SGLT2 inhibitor, characterizes exposure-urinary glucose excretion relationship in healthy subjects and type 2 diabetes mellitus patients. AAPS J 2010;12 Suppl. Abs R6400
15. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30:125-129
16. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Lab Clin Invest 1971;28: 101-109
17. Johansen K, Svendsen PA, Lørup B. Variations in renal threshold for glucose in Type 1 (insulin-dependent) diabetes mel-litus. Diabetologia 1984;26:180-182 (Pubitemid 14167796)
18. Ruhnau B, Faber OK, Borch-Johnsen K, Thorsteinsson B. Renal threshold for glucose in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1997;36: 27-33 (Pubitemid 27244820)
19. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem E-J. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetesdresults of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006;21:2166-2171 (Pubitemid 44295041)
20. Kashiwagi A, Takinami Y, Kazuta K, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improves glycemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type2diabetesmellitus: BRIGHTEN Study. [abstract OR149]. Presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, 12-16 September 2011, Lisbon, Portugal.
21. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-531
22. Piya MK, Tahrani AA, Barnett AH. Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol 2010;70:631-644
23. Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: A new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 2012;52:457-463
24. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-2224